Viral respiratory infections, including influenza and SARS-CoV-2, are well-documented triggers for both Type 1 and Type 2 myocardial infarction.
Do viral respiratory infections trigger myocardial infarction, and does influenza vaccination provide benefit in coronary artery disease patients?
Viral respiratory infections are important triggers for myocardial infarction, highlighting the potential protective role of influenza vaccination in patients with coronary artery disease.
Myocardial infarction (MI) is an acute clinical manifestation ischaemic heart disease, which is the leading cause of death worldwide. Infections also have an important burden worldwide, with lower respiratory infections being the worldwide leading cause of death due to communicable diseases. The relationship of MI with viral respiratory infections (including influenza and SARS-CoV-2) as a trigger has been well documented with significant associations. These infections can lead to Type 1 MI, where inflammation and vascular dysfunction, as well as the increased prothrombotic environment lead to atherothrombosis. Type 2 MI may also occur due to an imbalance of oxygen/blood supply and myocardial demand (hypoxaemia, fever, and tachycardia). The data from randomized controlled trials showing a potential benefit of influenza vaccination in coronary artery disease patients should not be ignored. This can be considered a further argument for the association of viral infections (influenza in particular) and MI.
Caldeira et al. (Tue,) conducted a review in Myocardial infarction and viral respiratory infections. Viral respiratory infections (including influenza and SARS-CoV-2) was evaluated. Viral respiratory infections, including influenza and SARS-CoV-2, are well-documented triggers for both Type 1 and Type 2 myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: